Dr. Peter K. Wayne, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 292
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 132616
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St John's Riverside Hospital Yonkers, NY
- St Joseph's Medical Center Yonkers, NY
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 292
- Services billed
- 651
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 125 | 101 |
| Established patient office or other outpatient visit, 10-19 minutes | 101 | 64 |
| Insertion of needle into vein for collection of blood sample | 96 | 54 |
| New patient office or other outpatient visit, 45-59 minutes | 89 | 89 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 50 | 49 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 45 | 45 |
| Biopsy of large bowel using a flexible endoscope | 42 | 41 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 28 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Yonkers, NY | 62 |
| Ursodiol Other prescribers in Yonkers, NY | 38 |
| Pantoprazole Sodium Other prescribers in Yonkers, NY | 31 |
| Omeprazole Other prescribers in Yonkers, NY | 30 |
| Famotidine Other prescribers in Yonkers, NY | 27 |
| Budesonide Dr (budesonide) Other prescribers in Yonkers, NY | 19 |
| Azathioprine Other prescribers in Yonkers, NY | 15 |
| Metronidazole Other prescribers in Yonkers, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 45 payments worth $1,144 in total to this clinician.
| AbbVie Inc. | $262 |
|---|---|
| Madrigal Pharmaceuticals | $251 |
| Gilead Sciences, Inc. | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | $157 |
| Ipsen Biopharmaceuticals, Inc | $136 |
| Intercept Pharmaceuticals, Inc. | $33.59 |
| Aimmune Therapeutics, Inc. | $22.72 |
| Novo Nordisk Inc | $19.06 |
| Food and Beverage | $1,144 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $98,891 in research payments for these studies, mostly to the institutions running them.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A phase 3B, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active crohns disease and o…
Eli Lilly and Company - A phase 3B, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active ulcerative colitis a…
Eli Lilly and Company - A master protocol for a randomized, controlled, clinical trial of multiple pharmacologic agents in adult participants with metabolic dysfunction-associated steatotic liver disease who are at increased risk of developi…
Eli Lilly and Company - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.